Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Research grant holder first to be graded at UFS in NRF’s Thuthuka Programme
2007-11-17

 

In the picture, from the left are: Ms Gudrun Schirge (National Research Foundation), Mr Nico Benson (Directorate Research Development at the UFS), Prof Heidi Hudson (Department of Political Science at the UFS) and Dr Annelize Venter (Co-ordinator of the Thuthuka Programme at the UFS)
Photo: Mangaliso Radebe

 

Research grant holder first to be graded at UFS in NRF’s Thuthuka Programme

Prof. Heidi Hudson, Departmental Chairperson at the University of the Free State's (UFS) Department of Political Science, recently received a C1 grading from the National Research Foundation (NRF).

With this grading she became the first researcher and grant holder in the Thuthuka Programme for young researchers at the UFS to be graded by the NRF.

“The Thuthuka Programme is a capacity building initiative from the NRF which prepares young researchers for grading and provides them with a good grounding for research,” said Dr Annelize Venter, researcher at the UFS Research Development Directorate and co-ordinator of the Thuthuka Programme.

According to Dr Venter, the UFS currently has 44 researchers who receive funding from the Thuthuka Programme for their postgraduate studies. The results of possible entrants to the programme in 2008 are awaited.

”The UFS also received ten researchers additional to the current 69 who have a valid evaluation status. The results of an additional 11 applications are also awaited. Some of these are first applications,” said Dr Venter.

Over and above the grant holders in the Thuthuka Programme, any researcher can apply to be evaluated by the NRF’s Evaluation Centre. The evaluation status of a researcher serves as the norm determinator and the quality of research at a university is measured according to this.

Ms Gudrun Schirge from the NRF presented a workshop today at the UFS to researchers who wanted to apply for grading and evaluation.
Researchers who wished to apply for the re-evaluation of their current evaluation status also attended the workshop.

Ms Schirge was one of the founders of the evaluation system and has been a manager at the Evaluation Centre for the past 20 years. She will be retiring this year and will be involved with the centre on a part-time basis.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
16 November 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept